Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

Ohio Attorney General Dave Yost issued a warning to several Ohio medical spas over their alleged claims regarding weight-loss drugs.

Several Ohio medical spas including two in the Mahoning Valley were sent letters by the Ohio Attorney General's Office ...

The Ohio attorney general's office issues warning letters to more than a dozen medical spas across the state for misleading claims about compounded versions of Ozempic, Wegovy and Mounjaro.

Three medical spas around the Valley, along with others in the state, were named by Attorney General Dave Yost for making ...

Ohio Attorney General Dave Yost announced Wednesday he sent letters to 14 medical spas, many in Northeast Ohio, warning them to stop making false or misleading claims about their versions of popular ...

Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide offerings.

By December 2023, 12.3% of all glucose-lowering medication dispensations were tirzepatide among adults with T2DM ...

Skye Bioscience currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug ...

If you’ve been using GLP-1 injectable medications like semaglutide and tirzepatide, what have you been doing with those used ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.